Progerinin
Phase 2Small molecule
Progerinin is one of 5 small molecule programs targeting Hutchinson-Gilford progeria syndrome. It is currently in Phase 2.
2
Indications
3
Total Trials
2
Active Trials
4
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
4 competitors in Hutchinson-Gilford Progeria Syndrome
#DrugCompanyPhaseTrials
1Zometa
PfizerApproved
Pravachol
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Approved
Zokinvy
SSentynl Therapeutics, Inc.
Phase 2
Progerinin
PPRG Science & Technology Co., Ltd.
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Hutchinson-Gilford progeria syndrome1 trial
Werner syndrome1 trial
Unspecified1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Progerinin. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details